Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pharmacokinetics and Pharmacodynamics of Valopictabine (nm283), a new nucleoside Hcv polymerase inhibitor: results from a phase I/ii dose-escalation trial in patients with Hcv-1 infection

Pharmacokinetics and Pharmacodynamics of Valopictabine (nm283), a new nucleoside Hcv polymerase inhibitor: results from a phase I/ii dose-escalation trial in patients with Hcv-1 infection. Gastroenterology. 2005; 128(4):a-700.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.